|
Assessment of MDRTB in bushehr province since 2009-2013
|
| Mohammadjavad Haerinejad1, Naghmeh Honarmand2, Saead Tajbakhsh3, Marzeah Shahin4, Omid Gharibi5, Katayon Vahdat *6 |
1- The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
2- Department of Communicable Diseases, Provincial Health Center, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Microbiology and Parasitology, Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
4- Faculty of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
5- Central Laboratory for tuberculosis, health center
6- The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran , vahdatpg@bpums.ac.ir, vahdatk@gmail.com |
|
|
Abstract: (1029 Views) |
Background: MDRTB has been identified as a developing threat , in recent years. MDRTB treatment costs 100times more than sensitive TB and requires intensive long time management and it has more health complications.
Materials & Methods: sputum samples were collected from all new cases of TB that faced with treatment failure in bushehr province between 2009 and 2013, and sent to Dr.Masih Daneshvari hospital for drug susceptibility test. In this study RFLP method was used for DNA isolation and PCR multiplex was used to assess drug sensitivity.
Results: we found 398 new cases of TB in three years of study, and 39 patients faced with treatment failure, finally six of them were reported as MDRTB (1.5%).
Conclusion: our data are close to the national statistics, however it is necessary to prevent further spread of resistant TB. |
|
| Keywords: Tuberculosis, Drug resistant, PCR multiplex |
|
|
Full-Text [PDF 351 kb]
(392 Downloads)
|
Type of Study: Original |
Subject:
Respiratory System
Received: 2015/11/8 | Accepted: 2015/11/8 | Published: 2015/11/8
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
